We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ABIO market cap is 417.81M. The company's latest EPS is USD -5.7712 and P/E is -1.98.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.97M | -1.94M | -1.59M | -2.48M | -3.12M |
| Net Income | -1.48M | -1.42M | -1.09M | -2.01M | -2.68M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -9.77M | -19.34M | -10.6M | -7.3M | -88.12M |
| Net Income | -9.74M | -19.32M | -9.93M | -5.34M | -83.72M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 41.08M | 39.18M | 37.86M | 36.71M | 33.84M |
| Total Liabilities | 1.85M | 1.22M | 841k | 1.58M | 1.27M |
| Total Equity | 39.24M | 37.97M | 37.02M | 35.13M | 32.57M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 50.43M | 54.92M | 43.09M | 37.86M | 396.02M |
| Total Liabilities | 3.91M | 3.88M | 1.41M | 841k | 13.8M |
| Total Equity | 46.52M | 51.04M | 41.67M | 37.02M | 379.29M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -2.29M | -3.96M | -5.01M | -1.53M | -4.16M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | N/A | N/A | N/A | N/A | 14k |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -7.73M | -18.76M | -10.91M | -5.01M | -57.84M |
| Investing | -19k | -43k | -2k | N/A | -330.13M |
| Financing | 48.45M | 23.09M | N/A | N/A | 449.54M |
| Market Cap | 417.81M |
| Price to Earnings Ratio | -1.98 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.69 |
| Price to Book Ratio | 0.43 |
| Dividend Yield | 5.52% |
| Shares Outstanding | 14.51M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.07 (2.89%) |
| Company Name | ARCA Biopharma Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.orukatx.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
